Development and validation of a nomogram based on stromal score to predict progression-free survival of patients with papillary thyroid carcinoma

被引:4
|
作者
Tang, Jiajia [1 ]
Jiang, Shitao [2 ]
Gao, Qiong [1 ]
Xi, Xuehua [3 ]
Gao, Luying [1 ]
Zhao, Ruina [1 ]
Lai, Xingjian [1 ]
Zhang, Bo [3 ]
Jiang, Yuxin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ultrasound, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Med Ultrason, Beijing, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 16期
基金
中国国家自然科学基金;
关键词
nomogram; papillary thyroid carcinoma; progression-free survival; stromal score; STAGING SYSTEM; ASSOCIATION GUIDELINES; CANCER; WELL; AGE; IDENTIFICATION; CUTOFF;
D O I
10.1002/cam4.4112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Growing evidence has proved that stromal cells, as the critical component of tumor microenvironment (TME), are closely associated with tumor's progression. However, the model based on stromal score to predict progression-free survival (PFS) in papillary thyroid carcinoma (PTC) has not been developed. The study aimed at exploring the relation between stromal score and prognosis, then establishing a nomogram to predict PFS of patients with PTC. Method We obtained the stromal score and clinicopathological characteristics of PTC patients from The Cancer Genome Atlas (TCGA) database. Cox regression analysis assisted in selecting prognosis-related factors. A stromal score-based nomogram was built and verified in the training and validation cohorts, respectively. The calibration curve, concordance index (C-index), decision curve analysis (DCA) as well as receiver operating characteristic (ROC) curve assisted in measuring the performance exhibited by the nomogram. Results We divided 381 PTC patients into the training cohort (n = 269) and the validation cohort (n = 112) randomly. Compared with patients who had a low stromal score, patients with a high stromal score appeared with significantly better PFS [Hazard ratio (HR) and 95% confidence interval (CI): 0.294, 0.130-0.664]. The C-index of the PFS nomogram was 0.764 (0.662-0.866) in the training cohort and 0.717 (0.603-0.831) in the validation cohort. The calibration curves for PFS prediction in the nomogram were remarkably consistent with the actual observation. DCA indicated superior performance of the nomogram to predict PFS than the American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) staging system. The ROC curves showed the favorable sensitivity and specificity of the novel nomogram. Conclusion High stromal score was significantly associated with improved PFS in patients with PTC. The nomogram based on the stromal score and clinicopathological patterns yielded a reliable performance to predict the prognosis of PTC.
引用
收藏
页码:5488 / 5498
页数:11
相关论文
共 50 条
  • [41] Development and validation of nomogram to predict overall survival and disease-free survival after surgical resection in elderly patients with hepatocellular carcinoma
    Tian, Yuan
    Wang, Yaoqun
    Wen, Ningyuan
    Lin, Yixin
    Liu, Geng
    Li, Bei
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] A Nomogram Predicting the Progression-Free Survival of Nonmetastatic Renal Cell Carcinoma Patients With Venous Thrombus After Surgery
    Zhang, Yu
    Tian, XiaoJun
    Bi, Hai
    Yan, Ye
    Liu, Zhuo
    Liu, Cheng
    Zhang, ShuDong
    Ma, LuLin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Development and validation of a nomogram to predict cancer-specific survival in middle-aged patients with papillary thyroid cancer: A SEER database study
    Tang, Jie
    Zhanghuang, Chenghao
    Yao, Zhigang
    Li, Li
    Xie, Yucheng
    Tang, Haoyu
    Zhang, Kun
    Wu, Chengchuang
    Yang, Zhen
    Yan, Bing
    HELIYON, 2023, 9 (02)
  • [44] Golgi-apparatus genes related signature for predicting the progression-free interval of patients with papillary thyroid carcinoma
    Liu, Rui
    Cao, Zhen
    Wu, Mengwei
    Li, Xiaobin
    Fan, Peizhi
    Liu, Ziwen
    BMC MEDICAL GENOMICS, 2023, 16 (01)
  • [45] Golgi-apparatus genes related signature for predicting the progression-free interval of patients with papillary thyroid carcinoma
    Rui Liu
    Zhen Cao
    Mengwei Wu
    Xiaobin Li
    Peizhi Fan
    Ziwen Liu
    BMC Medical Genomics, 16
  • [46] Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours
    Song, Wei
    Lv, Chang-guang
    Miao, Dong-liu
    Zhu, Zhi-gang
    Wu, Qiong
    Wang, Yong-gang
    Chen, Lei
    EJSO, 2018, 44 (10): : 1657 - 1665
  • [47] aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
    Vithayathil, Mathew
    D'Alessio, Antonio
    Fulgenzi, Claudia
    Celsa, Ciro
    Manfredi, Giulia
    Nishida, Naoshi
    Schoenlein, Martin
    von Felden, Johann
    Schulze, Kornelius
    Wege, Henning
    Saeed, Anwaar
    Wietharn, Brooke
    Hildebrand, Hannah
    Wu, Linda
    Ang, Celina
    Marron, Thomas U.
    Weinmann, Arndt
    Galle, Peter R.
    Bettinger, Dominik
    Lin, Chun-Yen
    Vogel, Arndt
    Scheiner, Bernhard
    Lee, Pei-Chang
    Huang, Yi-Hsiang
    Amara, Suneetha
    Muzaffar, Mahvish
    Naqash, Abdul Rafeh
    Zanuso, Valentina
    Pressiani, Tiziana
    Cabibbo, Giuseppe
    Dalbeni, Andrea
    Pinter, Matthias
    Singal, Amit
    Chon, Hong Jae
    Cortellini, Alessio
    Kudo, Masatoshi
    Rimassa, Lorenza
    Pinato, David J.
    Sharma, Rohini
    JOURNAL OF HEPATOLOGY, 2024, 80 : S443 - S443
  • [48] A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma
    Yang, Kaixuan
    Tian, Jiangfang
    Zhang, Bin
    Li, Mei
    Xie, Wenji
    Zou, Yating
    Tan, Qiaoyue
    Liu, Lihui
    Zhu, Jinbing
    Shou, Arthur
    Li, Guangjun
    ORAL ONCOLOGY, 2019, 98 : 85 - 91
  • [49] Primary hypertension to predict progression-free survival of target therapy in patients with metastatic renal cell carcinoma
    Chi, Zhi Hong
    Mao, Li Li
    Si, Lu
    Cui, Chuan Liang
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)